Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 5 months ago
Share
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
72 patients around the world
Available in
Brazil
Stanford University
72
Patients around the world
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Eligible for latent tuberculosis treatment by Brazil's national guidelines*
provides written informed consent to participate in the study
Exclusion criteria
Evidence of active tuberculosis or currently under evaluation for active tuberculosis
Receiving drugs that interact with Rifapentine (e.g. methadone, warfarin)
Known intolerance or hypersensitivity to isoniazid or rifapentine
Prior treatment for active or latent tuberculosis > 14 days
Close contact to isoniazid- or rifampicin-resistant tuberculosis (TB) case
Neutropenia (absolute neutrophil count <1000 cells/mm3)
Clinical diagnosis of active liver disease or alcohol dependence
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal
See details
Contact us
Contact us
Sponsor
Stanford University
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT05413551
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent